Amdinocillin
Coactin (amdinocillin) is a small molecule pharmaceutical. Amdinocillin was first approved as Coactin on 1984-12-21. It is used to treat bacterial infections, escherichia coli infections, gram-negative bacterial infections, klebsiella infections, and urinary tract infections in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
---|---|
infections | D007239 |
urogenital diseases | D000091642 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Amdinocillin
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
COACTIN | Roche | N-050565 DISCN | 1984-12-21 | 3 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
bacterial infections | — | D001424 | A49 |
escherichia coli infections | EFO_1001318 | D004927 | B96.20 |
gram-negative bacterial infections | — | D016905 | — |
klebsiella infections | EFO_1001353 | D007710 | — |
urinary tract infections | EFO_0003103 | D014552 | N39.0 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | AMDINOCILLIN |
INN | mecillinam |
Description | Mecillinam is a penicillin in which the 6beta substituent is [(azepan-1-yl)methylidene]amino; an extended-spectrum penicillin antibiotic that binds specifically to penicillin binding protein 2 (PBP2), and is only considered to be active against Gram-negative bacteria. It has a role as an antibacterial drug and an antiinfective agent. |
Classification | Small molecule |
Drug class | penicillins |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CC1(C)S[C@@H]2[C@H](/N=C/N3CCCCCC3)C(=O)N2[C@H]1C(=O)O |
Identifiers
PDB | — |
CAS-ID | 32887-01-7 |
RxCUI | 626 |
ChEMBL ID | CHEMBL530 |
ChEBI ID | — |
PubChem CID | 36273 |
DrugBank | DB01163 |
UNII ID | V10579P3QZ (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:

Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,564 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions

Mock data
Subscribe for the real data
Subscribe for the real data
10 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more